Repository hosted by TU Delft Library

Home · Contact · About · Disclaimer ·

Quality of life: 1. Perspectives

Publication files not online:

Author: Banta, H.D.
Institution: Nederlands Instituut voor Praeventieve Gezondheidszorg TNO
Source:Pharmacy World and Science, 2, 15, 45-49
Identifier: 232045
Keywords: Health · Drug therapy · Erythropoietin · Methods · Clinical trial · Economics · Health care · Human · Major clinical study · Methodology · Review · Cost-Benefit Analysis · Human · Quality of Life


Assessing the value of health care interventions is more and more a concern of governments, clinicians, health insurance companies, policy makers, and the general public. One dimension of the outcomes of such interventions that has received relatively little attention until recently is quality of life. However, during the last decade, measuring quality of life has become more frequent. Methodologies have also developed rapidly. At the same time, methodological problems continue to be troubling. In part, this explains the relative lack of use of validated measures of quality of life in clinical trials. In the future, measuring quality of life will certainly become more frequent. It may even be demanded by policy making bodies. Increasingly, too, economic costs will be part of such studies. This requires considering both clinical and economic data. Chemicals/CAS: erythropoietin, 11096-26-7